Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Comment by fezguyon Oct 17, 2007 12:41pm

218 Views

Post# 13588291

RE: Wonder if TKM knew about Merck/Protiva

As the article linked below suggests, I think Merck paid because the court injunction was delaying their RNAi research. So, although Merck may have been confident they would win the case against Protiva, they decided it was worth a few bucks to avoid the potentially long court delay. https://www.pharmalot.com/2007/10/merck-strikes-a-deal-with-a-troublemaker/ By the way, the Investor Village MB on ALNY often has posts on TKM. Here's the link: https://www.investorvillage.com/smbd.asp?mb=569&pt=m&pm=8651&nm=8675&sync=1

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!